These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33206282)

  • 1. SB8: A Bevacizumab Biosimilar.
    Syed YY
    Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
    Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D
    Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
    Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
    Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKB238: A Bevacizumab Biosimilar.
    Syed YY
    Clin Drug Investig; 2021 Sep; 41(9):825-828. PubMed ID: 34347284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYL-1402O: A Bevacizumab Biosimilar.
    Lee A
    Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FKB327: An Adalimumab Biosimilar.
    Al-Salama ZT
    BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
    Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
    Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GP2017: An Adalimumab Biosimilar.
    Heo YA
    BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D; Kim J; Yun J; Park SJ
    Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
    Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
    Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
    Li CSW; Sweeney K; Cronenberger C
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
    Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
    Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
    Rezvani H; Mortazavizadeh SM; Allahyari A; Nekuee A; Najafi SN; Vahidfar M; Ghadyani M; Khosravi A; Qarib S; Sadeghi A; Esfandbod M; Rajaeinejad M; Rezvani A; Hajiqolami A; Payandeh M; Shazad B; Anjidani N; Meskinimood S; Alikhasi A; Karbalaeian M; Salari S
    Clin Ther; 2020 May; 42(5):848-859. PubMed ID: 32334845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
    Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.